Popular Filters
Trials With No Placebo
Chemotherapy
DYP688 for Metastatic Uveal Melanoma
This trial is testing a new drug called DYP688 to see if it can help treat patients with specific types of skin cancer that have certain genetic mutations. The study aims to find out if the drug is safe and effective in shrinking tumors in these patients.
Checkpoint Inhibitor
Neoadjuvant Ipilimumab + Nivolumab for Melanoma
This trial is testing two treatment plans for patients with stage III melanoma. One plan uses two drugs before surgery, while the other uses surgery first followed by one of the drugs. The goal is to see which plan works better at stopping the cancer from coming back. These drugs have been shown to improve survival rates in patients with advanced melanoma.
Frequently Asked Questions
Introduction to malignant melanoma
What are the top hospitals conducting malignant melanoma research?
When it comes to cutting-edge clinical trials in the field of malignant melanoma, several renowned hospitals are leading the way. In Toronto, Sunnybrook Health Sciences Centre is actively conducting one trial for this aggressive form of skin cancer. While they may not have any previous trials specifically focused on malignant melanoma, their dedication to research and patient care remains unwavering. Similarly, Massachusetts General Hospital Hematology Oncology in Boston is also currently engaged in one active clinical trial for this condition with no prior recorded studies. This prestigious institution's commitment to advancing treatment options for patients with malignant melanoma highlights their continuous efforts to find new breakthroughs.
Heading towards New York City, Columbia University Medical Center - New York Presbyterian Oncology Department joins the ranks with an ongoing clinical trial focusing on malignant melanoma. Like its counterparts, there haven't been any past recorded trials related exclusively to this specific type of cancer at this facility; however, their active participation demonstrates a promising step forward in finding innovative approaches against this disease.
Meanwhile, another esteemed institution making waves in cancer research is Memorial Sloan Kettering Cancer Center (MSKCC) located in New York City as well. MSKCC boasts an ongoing clinical trial dedicated solely to investigating treatment options for malignant melanoma patients—a testament to their commitment and expertise in fighting against such diseases.
Finally, California Cancer Associates For Research (cCARE), situated in Encinitas, adds itself into the mix by conducting an active clinical trial targeting malignant melanoma cases within its region while having zero previously held investigations regarding such area uncovered up until now.
While these hospitals might not yet have extensive historical records when it comes to specific trials related directly to malignant melanoma treatment options – each represents a beacon of hope and progress within the medical community's relentless pursuit of improved outcomes for individuals afflicted by this challenging form of skin cancer. Through these collaborative efforts across various locations nationwide lies the potential for groundbreaking discoveries that could transform the lives of countless individuals affected by malignant melanoma.
Which are the best cities for malignant melanoma clinical trials?
When it comes to clinical trials for malignant melanoma, several cities stand out as key players in advancing research and treatment options. New York, New York, with 2 active trials studying DYP688 and other interventions. Encinitas, California also has 2 ongoing studies exploring treatments like Rituxan/Abraxane and others. Toronto, Ontario contributes to the field with 1 active trial focused on Treatment Arm and related approaches. Lastly, Boston, Massachusetts and Palm Springs, California both have 1 active trial each investigating treatments such as DYP688 and general therapeutic strategies respectively. These cities offer patients diagnosed with malignant melanoma access to cutting-edge clinical trials that hold promise for improved outcomes in the fight against this aggressive form of skin cancer.
Which are the top treatments for malignant melanoma being explored in clinical trials?
In the realm of clinical trials for malignant melanoma, several cutting-edge treatments are currently under exploration. Leading the pack is ipilimumab, a promising drug that has gained significant attention with its effectiveness in treating this aggressive form of skin cancer. Additionally, pembrolizumab and nivolumab have emerged as formidable contenders, demonstrating their potential to combat malignant melanoma through ongoing research studies. These innovative therapies offer hope for patients fighting against this challenging disease, paving the way for improved outcomes and enhanced quality of life.
What are the most recent clinical trials for malignant melanoma?
Recent clinical trials present new hope for those affected by malignant melanoma, a form of skin cancer. Notable among them is the investigation of DYP688, a potential treatment that has progressed to Phase 2 after promising results in Phase 1. Additionally, another trial focuses on developing an effective treatment arm specifically designed for malignant melanoma patients. These advancements highlight the ongoing efforts to combat this disease and improve outcomes for individuals facing this challenging diagnosis.
What malignant melanoma clinical trials were recently completed?
Several recent clinical trials have concluded, focusing on advancing treatments for malignant melanoma. Notably, a trial sponsored by Washington University School of Medicine was completed in October 2021, investigating the efficacy of Uproleselan. Additionally, the National Cancer Institute (NCI) wrapped up their own trial in September 2021, exploring mRNA-1273 therapy for this aggressive form of skin cancer. Finally, AgenTus Therapeutics successfully completed a study on agenT-797 in January 2021. These significant advancements highlight ongoing efforts to combat malignant melanoma and offer hope to patients facing this challenging condition.